Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | XBP1 | P17861 | 1/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1676958 | 0.89 | CNR1 (0.60) | CNR1HTTMAPTXBP1EPHX2 | |
| SCHEMBL27764417 | 0.87 | MAPT (0.83) | HTTMAPTXBP1EPHX2KMT2A | |
| SCHEMBL4012507 | 0.86 | MAPT (0.72) | HTTMAPTXBP1EPHX2SMN1; SMN2 | |
| SCHEMBL1677003 | 0.85 | CNR1 (0.56) | CNR1HTTMAPTXBP1EPHX2 | |
| SCHEMBL1677001 | 0.85 | CNR1 (0.56) | CNR1HTTMAPTXBP1EPHX2 | |
| SCHEMBL1677106 | 0.85 | CNR1 (0.56) | CNR1HTTMAPTXBP1EPHX2 | |
| SCHEMBL3964774 | 0.84 | MAPT (0.82) | HTTMAPTXBP1EPHX2LMNA | |
| SCHEMBL3959067 | 0.83 | MAPT (0.80) | HTTMAPTXBP1EPHX2SMN1; SMN2 | |
| SCHEMBL12310740 | 0.83 | ALDH1A1 (0.63) | CNR1HTTEPHX2LMNASMN1; SMN2 | |
| SCHEMBL1677199 | 0.83 | HTT (0.57) | CNR1HTTMAPTXBP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101679258-A | 4-piperidinylurea compounds as soluble epoxide hydrolase inhibitors | ARETE THERAPEUTICS INC | 2010-03-24 | — | — | CN | claimed |
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. | 2009-10-01 | — | — | US | claimed |
| WO-2009086426-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | WO | claimed |
| US-20080227780-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-09-18 | — | — | US | claimed |
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. | 2009-10-01 | — | — | US | disclosed |
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. | 2009-10-01 | — | — | US | disclosed |
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. | 2009-10-01 | — | — | US | disclosed |
| WO-2009086426-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086426-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2008112022-A1 | 4 -PI PERIDINYLUREA COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20080227780-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-09-18 | — | — | US | disclosed |
| US-20080227780-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-09-18 | — | — | US | disclosed |
| US-20080227780-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | EPHX1, ECE1, LIPG | CNR1 1611/4885HTT 4428/4885MAPT 3633/4885 |
| US-20080227780-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | CNR1 2108/4885HTT 4679/4885MAPT 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.